G-CSF administered to healthy volunteers at a dose of 3 g/kg for 5 days mobilized colony-forming units granulocyte-macrophage (CFU-GM), burst-forming unitserythroid (BFU-E), and long-term culture-initiating cells (LTC-IC) to a maximal level on day 4 or 5. To determine the number of primitive hematopoietic progenitors in the peripheral blood, mononuclear cells (MNCs) or CD34
Peripheral blood (PB) CD34
+ cells mobilized by chemotherapy with G-CSF are useful for rescuing cancer patients after marrow ablative therapy. [1] [2] [3] [4] Recently, PB CD34 + cells mobilized with G-CSF alone have been successfully used as a source of allogeneic stem cells for transplantation. [5] [6] [7] The usual dose of G-CSF used is 10 g/kg for 5 consecutive days to obtain sufficient numbers of PB CD34 + cells. However, it remains unclear whether the low dose of G-CSF mobilizes sufficient numbers of primitive progenitors from healthy donors and when apheresis should be timed to harvest the greatest number of primitive progenitors. CD34 + cells are heterogeneous; they contain differentiated and primitive progenitors. Phenotypes + cells before and after G-CSF administration. 8 Using a long-term culture (LTC) system, we analyzed characteristics of PB CD34
+ cells from healthy volunteers administered G-CSF and patients treated with chemotherapy plus G-CSF.
Materials and methods

PB and BM samples
PB samples were independently obtained from five healthy volunteers (PB-SS), four healthy volunteers administered G-CSF (PB-G), and eight patients with malignancy (PB-CG) (three ALL; two non-Hodgkin lymphoma (NHL); three ovarian cancer). All volunteers and patients gave their informed consent. Leukapheresis products were harvested, using an automated continuous-flow blood cell separator (Spectra; Cobe Laboratories, Engelwood, CO, USA).
Before leukapheresis products were harvested, patients with ALL and NHL were treated with high-dose ara-C (2 g/m 2 twice daily i.v. for 2 days). Patients with ovarian cancer were treated with cisplatin (70 mg/m 2 i.v. on day 1) and CY (1400 mg/m 2 i .v. on day 1). All treatments were followed by G-CSF (lenograstim; Chugai Pharmaceutical, Tokyo, Japan) rescue at a dosage of 3 g/kg. Leukapheresis was conducted when the leukocyte count was greater than 5000/l. The average leukocyte count at harvest was 17 200/l (range: 8500-39 700/l). BM samples were obtained from five healthy volunteers. PB and BM samples were layered over Ficoll-Hypaque (Lymphoprep; Nycomed Pharma, Oslo, Norway) and centrifuged at 0.4 g for 30 min. Mononuclear cells (MNCs) were collected, washed twice, and counted.
G-CSF administration into healthy volunteers
G-CSF (lenograstim) was injected subcutaneously into four healthy volunteers daily for 5 consecutive days at a dose of 3 g/kg. On days 0, 2, 3, 4, 5, 6 and 10, PB samples were collected to evaluate WBC count, hemogram, colonyforming celIs (CFCs) and LTC-IC. Apheresis was performed on day 5. For two volunteers, the MNCs collected daily were cultured in LTC and the number of CFCs evaluated for 7 weeks.
Enrichment of CD34
+ cells CD34 + cells were enriched from PB or BM MNCs using a direct immunoadherence panning technique (MicroCELLector; Applied Immune Science (AIS), Menlo Park, CA, USA) as described. 9 Briefly, mature differentiated cells adhering to flasks coated with soybean agglutinin (SBA) were removed. Non-adherent cells were then incubated in flasks coated with anti-CD34 monoclonal antibody (ICH3; AIS) for 60 min at 37°C. CD34
+ cells binding to the antibody were mechanically removed from the flasks. Preliminary experiments showed that the purity of the CD34 + cells enriched from PB MNCs was not high enough. Therefore, before the enrichment process, we removed mature T and B lymphocytes from PB MNCs. PB MNCs were incubated with a mixture of magnetizable polystyrene beads (Dynabeads M-450; Dynal, Oslo, Norway) coated with anti-CD2, anti-CD4, anti-CD8 and anti-CD19 for 30 min at 4°C, and then the cells combined with the beads were removed using a magnet, as reported previously. 8 With this procedure, the purity of CD34 + cells enriched from PB MNCs was over 90%.
Two-stage long-term culture
The capacity of the MNCs and CD34 + cells to repopulate BM stromal cells was tested in a two-stage long-term culture system, as described. [10] [11] [12] Briefly, 3 ϫ l0 6 BM MNCs were plated in flasks containing 5 ml IMDM (GIBCO, Long Island, NY, USA) with 12.5% FCS (Flow Laboratories, North Ryde, NSW, Australia), 12.5% horse serum (JRH Bioscience, Lenexa, KS, USA), 10 Ϫ4 m 2-ME (Sigma Chemical, St Louis, MO, USA), 10 Ϫ6 m hydrocortisone (Japan Upjohn, Tokyo, Japan), 100 U/ml penicillin (GIBCO) and 100 U/ml streptomycin (GIBCO). Flasks were cultured in a humidified 5% CO 2 atmosphere at 33°C for 2-4 weeks. When the stromal layer in a flask reached confluence, it was removed with 0.25% tripsin (Sigma Chemical) and the cells were subcultured at 1 ϫ 10 5 in 24-well plates. After the cells reached confluence, they were exposed to 1500 cGy irradiation. 0.4-2 ϫ 10 5 MNCs or 0.5-2 ϫ 10 3 CD34 + cells enriched from PB or BM MNCs were plated on allogeneic irradiated stromal cell layers in 1.5 ml of long-term cultured medium (IMDM with 12.5% FCS, 12.5% horse serum, 2 mm lglutamine (Sigma), 100 U/ml penicillin, 100 U/ml streptomycin and 10 Ϫ6 m hydrocortisone). All cultures were maintained in a humidified 5% CO 2 atmosphere at 37°C. Half of the supernatant was removed weekly, and the culture was replenished with fresh long-term culture medium. Every week until week 7, both non-adherent and adherent cells were harvested from two to three wells and assayed for CFCs as mentioned below. The total number of CFCs (ie CFU-GM plus BFU-E) at week 5 was divided by 4 and this value was defined as LTC-IC. The number '4' calculated with limiting dilution assay was reported on BM and PB samples.
13,14
Colony assay for CFU-GM and BFU-E
Colony assay was performed in 1.2% methylcellulose (Aldrich Chemical, Milwaukee, WI, USA) with IMDM Day 10
Week of culture Figure 3 Number of CFU-GM and BFU-E produced weekly by PB MNCs in LTC after administration of G-CSF into healthy volunteers. 1 ϫ 10 5 PB MNCs were collected for 10 days after G-CSF administration into healthy volunteers and subjected to LTC for 7 weeks. Every week, the CFU-GM (Ǣ) and BFU-E (a) produced by the cultured cells were enumerated.
supplemented with 30% FCS, 1% deionized BSA (Sigma Chemical), 5 ϫ 10 Ϫ5 m 2-ME, 5% PHA-stimulated condition medium (PHA-LCM), and 2 U/ml of recombinant human Epo (Chugai Chemical). Enriched CD34 + cells and MNCs before long-term culture were adjusted to a final concentration of 1 ϫ 10 3 /ml and 1 ϫ 10 5 /ml, respectively. All the non-adherent and adherent cells recovered from stromal layers in a single well were assayed in the same medium without adjustment of cell count. One milliliter aliquots of the cell mixture were put in 35 mm plastic culture dishes and incubated for 14 days at 37°C in a 5% CO 2 incubator. After 14 days incubation, colonies derived from CFU-GM and BFU-E were counted under an inverted microscope. Aggregates of more than 40 non-hemoglobinized cells were scored as CFU-GM and three or more clusters each with more than 40 hemoglobinized cells were scored as BFU-E.
Statistical analysis
Results were expressed as the mean Ϯ standard deviation (s.d.). Statistical analysis was carried out by Student's ttest.
Results
Kinetics of leukocytes, CFCs (CFU-GM and BFU-E), and primitive progenitors (LTC-IC) in PB MNCs mobilized by G-CSF
PB MNCs were assayed for colony-forming and LTC ability after administration of G-CSF into healthy volunteers. Figure 1a and b show the absolute number of leukocytes, neutrophils, CFU-GM, and BFU-E per one ml of PB from four healthy volunteers after G-CSF administration at a dose of 3 g/kg for 5 days. Slight bone pain was experienced by two volunteers. However, no other adverse effects including fever, allergy, or platelet reduction were observed. The number of leukocytes, neutrophils, CFU-GM, and BFU-E maximized on day 4 or day 5 and then rapidly decreased. The number of CFU-GM and BFU-E had not returned to the basal level by day 10. The magnitude of the peak increase in CFU-GM and BFU-E was 44.5-and 12.8-fold, respectively. LTC-ICs were undetectable on day 0, increased in number to a maximum value on day 4, then decreased rapidly (Figure 2) .
On day 5 of G-CSF administration, leukapheresis was performed on all volunteers for 45 min. The overall yield of all nucleated cells, CD34
+ cells, CFU-GM, BFU-E and 
Analysis of LTC of PB MNCs after G-CSF administration into healthy volunteers
To determine the kinetics of PB progenitors mobilized with G-CSF, PB MNCs from two healthy volunteers administered G-CSF were harvested on day 0 to day 10. The MNCs were cultured using the LTC system for 7 weeks. The number of CFU-GM and BFU-E in wells was evaluated every week. As shown in Figure 3 , on each day after G-CSF administration, PB MNCs produced the largest number of CFU-GM at week 1 or week 2 of LTC. Following G-CSF administration, PB MNCs represented the majority of CFU-GM on days 4-6. As PB MNCs collected on each day after G-CSF administration might contain progenitors at different stages of maturation, we separated the two types of progenitors, using LTC. Differentiated and primitive progenitors were defined as cells producing colonies at weeks 2 and 5, respectively. Figure 4 shows the kinetics of the percentage of the total number of colonies produced by LTC from PB MNCs collected from days 0 to 10. The total number of colonies produced by PB MNCs collected on days 0-10 at weeks 2 and 5 of LTC was divided by that at week 0. In both cases, the colonies collected at week 2 increased in number from day 4 and peaked on day 6. In contrast, colonies collected at week 5 peaked on day 4 and then decreased.
Characteristics of enriched CD34 + celIs from mobilized PB MNCs
The numbers of CFU-GM per 1 ϫ 10 3 CD34 + cells from PB-SS (steady-state), PB-G (G-CSF-mobilised), PB-CG (chemotherapy and G-CSF-mobilised) and BM were 17.4 Ϯ 12.9, 43.2 Ϯ 21.0, 78.4 Ϯ 37.8 and 80.4 Ϯ 19.9, respectively, and those of BFU-E were 164.2 Ϯ 39.2, 178.6 Ϯ 41.8, 102.0 Ϯ 36.9 and 41.6 Ϯ 23.8, respectively. The number of CFU-GM and BFU-E in CD34
+ cells from PB-G was nearly equal to that from PB-SS. In PB-CG, the number of CFU-GM was greater, while the number of BFU-E was significantly less than in PB-SS and PB-G. However, the number of total CFCs (CFU-GM plus BFU-E) was not significantly different among the various types of PB CD34 + cells. CD34
+ cells enriched from PB or BM MNCs were cultured by LTC for 5-7 weeks and assayed for CFCs every week ( Figure 5 ). The total number of colonies produced by CD34 + cells from both PB-SS and PB-G peaked at weeks 1 or 2 and then abruptly decreased until week 5. In CD34 + cells from PB-CG, two types were identified; in the cases where the total number of colonies at week 5 of LTC were less than 100 per 1 ϫ 10 3 initiating CD34 + cells before LTC, the CD34 + cells from PB-CG were defined as type 1. In the others, the CD34 + cells from PB-CG were defined as type 2 . Type 1, in which the total number of colonies increased rapidly, peaked at weeks 1 or 2, and then decreased abruptly, and type 2, in which the total number of colonies gradually increased, peaked at 2-4 weeks, then decreased slowly, retaining a high value (more than 100 per 10 3 CD34 + cells) even at week 5. The total number of colonies produced by BM CD34 + celIs at week 2 was lower than that from all other PB CD34
+ cells. Figure 6 shows the number of differentiated and primitive progenitors. As mentioned above, differentiated and primitive progenitors were defined as cells producing colonies at week 2 and week 5 of LTC, respectively. The number of differentiated progenitors was the greatest in PB-CG (type 1). The number of differentiated progenitors from PB-G was nearly equal to that from PB-SS. On the other hand, the number of primitive progenitors was the greatest in PB-CG (type 2) and was the least in PB-G.
Discussion
PBSCs have been used as a source of hematopoietic stem cells for autologous transplantation, following bone marrow ablative chemotherapy. [1] [2] [3] [4] Moreover, PBSCs have been successfully used for allogeneic stem cell transplantation. [5] [6] [7] Although PBSCs are known to be mobilized upon G-CSF treatment, the minimum dose of G-CSF necessary to harvest enough PBSCs for hematopoietic reconstitution has not been determined. The ability of G-CSF to mobilize + cells from PB and BM after LTC. 1 ϫ 10 3 CD34 + cells enriched from PB or BM were subjected to LTC for 7 weeks. Every week, cultured CD34 + cells were assayed for colony-forming ability. PB CD34 + cells were harvested from healthy volunteers treated without G-CSF (PB-SS), and with it (PB-G), and patients treated with chemotherapy plus G-CSF rescue (PB-CG). PB-CG were further divided into two groups (type 1 and type 2).
LTC of PB CD34
+ cells T Suzuki et al PBSCs into PB is dose-dependent, 15, 16 and the most common dose of G-CSF used is 10 g/kg s.c., [5] [6] [7] however, high doses of G-CSF, especially over 10 g/kg, have adverse effects on healthy donors such as platelet reduction and severe bone pain. Therefore, we examined whether a relatively low dose of G-CSF (3 g/kg for 5 consecutive days) is sufficient to mobilize PBSCs. Approximately 0.7 ϫ 10 6 /kg CD34 + cells were harvested in 45 min of apheresis. Thus, if 2-3 ϫ 10 6 CD34 + cells per kg are required to perform allogeneic PBSCT 17 and the contents of leukapheresis products are constant after 45 min, the apheresis takes 3-4 h.
It is unclear whether primitive cells defined as LTC-IC and CFCs defined as CFU-GM and BFU-E appear in the PB circulation at the same time after G-CSF administration. As described previously, 18 in patients treated with chemotherapy plus G-CSF rescue, primitive cells (Thy-1 + cells) appear mainly in the PB circulation at an early stage, while differentiated cells (Thy-1 Ϫ cells) are present at a late stage. Although we also investigated the level of CD33, CD13, CD117 (c-kit) and CD90 (Thy-1) on CD34
+ cells before and after G-CSF administration, the difference in these surface antigens was not clear (data not shown). Therefore, to analyze the number of primitive and differentiated progenitors in PB MNCs mobilized on administration of G-CSF into healthy volunteers, PB MNCs collected daily after G-CSF treatment were subjected to LTC. This system distinguishes primitive from differentiated progenitors of MNCs and CD34
+ cells. 12, 19 We defined the number of colonies produced by the cells cultured in the LTC system at week 2 as differentiated progenitors and those at week 5 as primitive progenitors.
The LTC system revealed that G-CSF administered into healthy volunteers mobilized more primitive progenitors into PB on days 3-5 than on days 2, 6, and 10, while differentiated progenitors increased in number from day 4. These results indicate that apheresis should be conducted on days 4 and 5 after G-CSF administration, because at that time, the greatest number of both primitive and differentiated progenitors appear in PB circulation; the former are involved in bone marrow reconstitution, while the latter proliferate and differentiate soon after the transplant, and defend the recipients against infection in an early posttransplant period. Days 4 and 5 as the optimal time for apheresis to harvest a sufficient amount of PBSCs is supported by several studies. [5] [6] [7] 17 It is unclear why there is a time lag in the movement of primitive progenitors from BM into PB after G-CSF administration 20 and why differentiated progenitors are relatively more abundant in the latter phase of the treatment. Primitive progenitors may not be affected with G-CSF directly and be pushed out together with BFU-E and CFU-GM into PB from BM filled with an increased number of differentiated progenitors and mature cells after G-CSF administration. However, mobilization of these primitive progenitors is finished to some extent, while differentiated progenitors and mature cells may increase gradually in number in BM and move into PB mainly in the latter phase. CD34 + cells from PB-CG could be characterized into two different types (type 1 and type 2); type 1 contained more differentiated and less primitive progenitors than type 2 CD34 + cells. Surface antigen analyses of CD34 + cells showed no differences between type 1 and type 2 cells. Although we investigated any other factors such as prior treatment, disease, leukocyte count on apheresis time and type of chemotherapy, from which the two different types may derive, we could not find out the factors. As reported previously, 8, 21, 22 PB CD34 + cells from PB-CG contain primitive and differentiated progenitors with a wide range of the ratio of CFU-GM to BFU-E and frequency of CD33, CD13, CD38, CD90 and CD117 on CD34 + cells. Variations in CD34
+ cell maturation among leukapheresis products from PB-CG may depend on the sum of the frequency and regimen of chemotherapy, timing of apheresis, and dose of G-CSF. PB CD34 + cells from PB-G contained less primitive progenitors than those from PB-CG. The absolute number of CD34 + cells was certainly much greater in PB-G than in PB-SS even at a relatively low dose of G-CSF. Therefore, although it is possible that at a dose of 3 g/kg of G-CSF sufficient numbers of PB CD34
+ cells for hematopoietic reconstitution are collected, PB CD34
+ cells from PB-G should be harvested from donors as much as possible. It is important that the CD34 + cells of PB-CG contained more primitive cells than those of PB-G, since the same dose of G-CSF was administered in both cases. These results indicate that cytoreductive chemotherapy plays an important role in the mobilization of primitive progenitors. Chemotherapy may increase the amount of endogenous cytokines or alter adhesion molecules of stromal cells.
